A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Second-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Trial Profile

A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Second-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2015

At a glance

  • Drugs Tasisulam (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Jun 2015 Planned End Date changed from 1 Aug 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
    • 19 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top